ATE542820T1 - Pteridinderivate als inhibitoren der polo-like- kinase zur behandlung von krebs - Google Patents

Pteridinderivate als inhibitoren der polo-like- kinase zur behandlung von krebs

Info

Publication number
ATE542820T1
ATE542820T1 AT07824247T AT07824247T ATE542820T1 AT E542820 T1 ATE542820 T1 AT E542820T1 AT 07824247 T AT07824247 T AT 07824247T AT 07824247 T AT07824247 T AT 07824247T AT E542820 T1 ATE542820 T1 AT E542820T1
Authority
AT
Austria
Prior art keywords
optionally substituted
ring
polo
treatment
alkyl
Prior art date
Application number
AT07824247T
Other languages
English (en)
Inventor
David Festus Charles Moffat
Sanjay Ratilal Patel
Stephen John Davies
Kenneth William John Baker
Oliver James Philps
Original Assignee
Chroma Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0621205A external-priority patent/GB0621205D0/en
Priority claimed from GB0715614A external-priority patent/GB0715614D0/en
Application filed by Chroma Therapeutics Ltd filed Critical Chroma Therapeutics Ltd
Application granted granted Critical
Publication of ATE542820T1 publication Critical patent/ATE542820T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT07824247T 2006-10-25 2007-10-19 Pteridinderivate als inhibitoren der polo-like- kinase zur behandlung von krebs ATE542820T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0621205A GB0621205D0 (en) 2006-10-25 2006-10-25 Inhibitors of PLK
GB0715614A GB0715614D0 (en) 2007-08-10 2007-08-10 Inhibitors of plk
PCT/GB2007/003998 WO2008050096A1 (en) 2006-10-25 2007-10-19 Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE542820T1 true ATE542820T1 (de) 2012-02-15

Family

ID=38896021

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07824247T ATE542820T1 (de) 2006-10-25 2007-10-19 Pteridinderivate als inhibitoren der polo-like- kinase zur behandlung von krebs

Country Status (13)

Country Link
US (1) US20100216802A1 (de)
EP (1) EP2079743B1 (de)
JP (1) JP2010507639A (de)
KR (1) KR20090071668A (de)
AT (1) ATE542820T1 (de)
AU (1) AU2007310604B2 (de)
BR (1) BRPI0718120A2 (de)
CA (1) CA2665736A1 (de)
EA (1) EA200900593A1 (de)
IL (1) IL198082A0 (de)
MX (1) MX2009004244A (de)
NZ (1) NZ577153A (de)
WO (1) WO2008050096A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
JP5043120B2 (ja) * 2006-10-30 2012-10-10 クロマ セラピューティクス リミテッド ヒストンデアセチラーゼの阻害剤としてのヒドロキサメート
JP5406725B2 (ja) 2006-12-14 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼ阻害剤として有用な化合物
GB0803747D0 (en) 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
GB0807451D0 (en) * 2008-04-24 2008-05-28 Chroma Therapeutics Ltd Inhibitors of PLK
AU2009271663B2 (en) * 2008-06-23 2014-04-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
WO2010008454A1 (en) 2008-06-23 2010-01-21 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
KR20120081119A (ko) * 2009-09-04 2012-07-18 잘리커스 파마슈티컬즈 리미티드 통증 및 간질 치료를 위한 치환된 헤테로고리 유도체
CN102020643A (zh) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
RS56184B1 (sr) 2012-10-17 2017-11-30 Macrophage Pharma Ltd Terc-butil n-[2-{4-[6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1(2h)-il]-3,5-difluorofenil}etil]-l-alaninat ili njegova so, hidrat ili solvat
US10208023B2 (en) 2013-03-01 2019-02-19 Mark G. DeGiacomo Heterocyclic inhibitors of the sodium channel
WO2015116696A1 (en) 2014-01-28 2015-08-06 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
EP3099693A4 (de) 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Verwendungen von diazepinderivaten
MX2016009975A (es) * 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de dihidropteridinona y sus usos.
KR20160115953A (ko) 2014-01-31 2016-10-06 다나-파버 캔서 인스티튜트 인크. 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도
MX2018003031A (es) 2015-09-11 2018-08-01 Dana Farber Cancer Inst Inc Ciano tienotriazolpirazinas y usos de las mismas.
BR112018009798A8 (pt) 2015-11-25 2019-02-26 Dana Farber Cancer Inst Inc inibidores de bromodomínio bivalentes e usos dos mesmos
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use
EP3833353A4 (de) * 2018-08-10 2022-08-24 Yale University Kleinmolekulare pi5p4k-alpha/beta-inhibitoren und verfahren zur behandlung damit
CN111039944B (zh) * 2018-10-12 2021-11-23 中国科学院合肥物质科学研究院 Mst1激酶抑制剂及其用途
KR102260995B1 (ko) * 2018-11-28 2021-06-04 국립암센터 Plk1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
CN115947728B (zh) * 2021-10-09 2024-01-09 沈阳药科大学 含磺酰基的二氢喋啶酮衍生物及其应用
WO2023158514A1 (en) 2022-02-18 2023-08-24 Massachusetts Institute Of Technology Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization
CN118047779A (zh) * 2022-11-09 2024-05-17 沈阳药科大学 含苯联杂芳基的二氢喋啶酮衍生物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1786817A1 (de) * 2004-08-26 2007-05-23 Boehringer Ingelheim International GmbH Pteridinone als plk (polo like kinase) inhibitoren
WO2006021548A1 (de) * 2004-08-27 2006-03-02 Boehringer Ingelheim International Gmbh Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel

Also Published As

Publication number Publication date
AU2007310604A1 (en) 2008-05-02
US20100216802A1 (en) 2010-08-26
MX2009004244A (es) 2009-05-14
IL198082A0 (en) 2009-12-24
AU2007310604B2 (en) 2012-02-02
WO2008050096A1 (en) 2008-05-02
EP2079743A1 (de) 2009-07-22
BRPI0718120A2 (pt) 2013-11-12
KR20090071668A (ko) 2009-07-01
CA2665736A1 (en) 2008-05-02
EA200900593A1 (ru) 2010-06-30
EP2079743B1 (de) 2012-01-25
NZ577153A (en) 2012-02-24
JP2010507639A (ja) 2010-03-11

Similar Documents

Publication Publication Date Title
ATE542820T1 (de) Pteridinderivate als inhibitoren der polo-like- kinase zur behandlung von krebs
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
MX2012002059A (es) Compestos heterociclicos triciclicos como inhibidores de fosfoionositida 3-quinasa.
BR0316146A (pt) Derivados de amida do ácido 3-(2-hidróxifenil)-1h-pirazol-4-carboxìlico como inibidores de hsp90 para o tratamento de câncer
PE20151981A1 (es) Pontenciador de inhibidores del homologo de zeste
PE20120506A1 (es) Derivados de pirazolopiridina como inhibidores de quinasas
AR067599A1 (es) Derivados de indazol sustituido activos como inhibidores de quinasa
PE20120058A1 (es) Derivados de imidazopirazina como inhibidores de syk
TW200714589A (en) Phenylacetamides suitable as protein kinase inhibitors
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
TN2010000293A1 (en) Thiazole derivatives used as pi 3 kinase inhibitors
AR077975A1 (es) Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
TW200942541A (en) Polysubstituted 6-heteroarylimidazo[1,2-α]pyridine derivatives, preparation thereof and therapeutic use thereof
MY148566A (en) Crystalline solvates and complexes of (is) -1, 5- anhydro-1 -c-(3-( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
MX2009013218A (es) Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus.
PE20060842A1 (es) Amino-imidazolonas para la inhibicion de b-secretasa
PE20130149A1 (es) Derivados de la cromenona con actividad anti-tumoral
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
PE20110213A1 (es) Derivados de indolinona como inhibidores de quinasa
MX2010000658A (es) Derivados de pirimidina 934.
IL198267A0 (en) Ikk-?? serine-threonine protein kinase inhibitors
MX2021004380A (es) Derivados de flavaglina para inhibicion de activacion del oncogen kras.
AR058329A1 (es) Derivados de pirazolo (4,3-c) piridina sustituidos activos como inhibidores de quinasa, un metodo para su preparacion y composicion farmaceutica
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
PH12018502411A1 (en) Novel 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one derivative